Choroidal Neovascularization Market to Witness Upsurge in Growth During the Forecast Period (2023-2032), Examine DelveInsight | Abbvie, Sylentis, Ixoberogene soroparvovec, Novartis, Hoffmann-La Roche

Posted on
by

Choroidal Neovascularization Market to Witness Upsurge in Growth During the Forecast Period (2023-2032), Examine DelveInsight | Abbvie, Sylentis, Ixoberogene soroparvovec, Novartis, Hoffmann-La Roche
DelveInsight’s “Choroidal Neovascularization Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Choroidal Neovascularization, historical and forecasted epidemiology as well as the Choroidal Neovascularization market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

DelveInsight’s “Choroidal Neovascularization Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Choroidal Neovascularization, historical and forecasted epidemiology as well as the Choroidal Neovascularization market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Choroidal Neovascularization market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Choroidal Neovascularization Market Forecast

 

Some of the key facts of the Choroidal Neovascularization Market Report: 

  • The Choroidal Neovascularization market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • In July 2023, Fresh clinical findings and real-world data presented at the American Society of Retina Specialists (ASRS) Annual Meeting demonstrate enhanced outcomes for individuals dealing with wet Age-Related Macular Degeneration (AMD) using Genentech’s VABYSMO.
  • In January 2022, The US FDA granted approval to Genentech’s VABYSMO, marking the first bispecific antibody sanctioned for treating wet, or neovascular, Age-Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME). VABYSMO works by targeting and blocking two disease pathways associated with various vision-threatening retinal conditions—neutralizing angiopoietin-2 (Ang-2) and VEGF-A.
  • As per the 2023 report from the American Academy of Ophthalmology, individuals aged 50 and above face a higher likelihood of developing choroidal neovascular membranes (CNVM). The risk of CNVM tends to rise with age, particularly because most CNVM cases are linked to wet age-related macular degeneration. People who experience eye injuries or possess risk factors for different eye conditions might develop CNVM at an earlier stage in life.
  • Key Choroidal Neovascularization Companies: Abbvie, Sylentis, Ixoberogene soroparvovec, Novartis, Hoffmann-La Roche, Mateon Therapeutics, QLT Inc., Eyetech Pharmaceuticals, Allergan, Mateon Therapeutics, Genentech, Inc., Allergan, ICON Bioscience, and others
  • Key Choroidal Neovascularization Therapies: ABBV-RGX-314, SYL1801, Adverum, ranibizumab 0.5mg, Faricimab, Combretastatin A-4 Phosphate, verteporfin, EYE001 anti-VEGF aptamer, dexamethasone, fosbretabulin, rhuFab V2, AGN211745, IBI-20089/Lucentis, and others
  • The Choroidal Neovascularization market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Choroidal Neovascularization pipeline products will significantly revolutionize the Choroidal Neovascularization market dynamics.

  

Get a Free sample for the Choroidal Neovascularization Market Report 

https://www.delveinsight.com/report-store/choroidal-neovascularization-market

 

Choroidal Neovascularization Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Choroidal Neovascularization Epidemiology Segmentation:

The Choroidal Neovascularization market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Choroidal Neovascularization
  • Prevalent Cases of Choroidal Neovascularization by severity
  • Gender-specific Prevalence of Choroidal Neovascularization
  • Diagnosed Cases of Episodic and Chronic Choroidal Neovascularization

 

Download the report to understand which factors are driving Choroidal Neovascularization epidemiology trends @ Choroidal Neovascularization Epidemiology Forecast

 

Choroidal Neovascularization Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Choroidal Neovascularization market or expected to get launched during the study period. The analysis covers Choroidal Neovascularization market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Choroidal Neovascularization Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Choroidal Neovascularization Therapies and Key Companies

  • ABBV-RGX-314: Abbvie
  • SYL1801: Sylentis
  • Adverum: Ixoberogene soroparvovec
  • ranibizumab 0.5mg: Novartis
  • Faricimab: Hoffmann-La Roche
  • Combretastatin A-4 Phosphate: Mateon Therapeutics
  • verteporfin: QLT Inc.
  • EYE001 anti-VEGF aptamer: Eyetech Pharmaceuticals
  • dexamethasone: Allergan
  • fosbretabulin: Mateon Therapeutics
  • rhuFab V2: Genentech, Inc.
  • AGN211745: Allergan
  • IBI-20089/Lucentis: ICON Bioscience

 

Discover more about therapies set to grab major Choroidal Neovascularization market share @ Choroidal Neovascularization Treatment Market

 

Choroidal Neovascularization Market Strengths

  • There has been growing awareness and understanding of CNV in recent years, which has led to increased investment in research and development. This is likely to continue, further accelerating the development of new treatments

 

Choroidal Neovascularization Market Opportunities

  • CNV is a leading cause of vision loss in adults, and there are currently limited treatment options available. This presents a significant opportunity for the development of new and effective therapies.

 

Scope of the Choroidal Neovascularization Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Choroidal Neovascularization Companies: Abbvie, Sylentis, Ixoberogene soroparvovec, Novartis, Hoffmann-La Roche, Mateon Therapeutics, QLT Inc., Eyetech Pharmaceuticals, Allergan, Mateon Therapeutics, Genentech, Inc., Allergan, ICON Bioscience, and others
  • Key Choroidal Neovascularization Therapies: ABBV-RGX-314, SYL1801, Adverum, ranibizumab 0.5mg, Faricimab, Combretastatin A-4 Phosphate, verteporfin, EYE001 anti-VEGF aptamer, dexamethasone, fosbretabulin, rhuFab V2, AGN211745, IBI-20089/Lucentis, and others
  • Choroidal Neovascularization Therapeutic Assessment: Choroidal Neovascularization current marketed and Choroidal Neovascularization emerging therapies
  • Choroidal Neovascularization Market Dynamics: Choroidal Neovascularization market drivers and Choroidal Neovascularization market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Choroidal Neovascularization Unmet Needs, KOL’s views, Analyst’s views, Choroidal Neovascularization Market Access and Reimbursement 

 

To know more about Choroidal Neovascularization companies working in the treatment market, visit @ Choroidal Neovascularization Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Choroidal Neovascularization Market Report Introduction

2. Executive Summary for Choroidal Neovascularization

3. SWOT analysis of Choroidal Neovascularization

4. Choroidal Neovascularization Patient Share (%) Overview at a Glance

5. Choroidal Neovascularization Market Overview at a Glance

6. Choroidal Neovascularization Disease Background and Overview

7. Choroidal Neovascularization Epidemiology and Patient Population

8. Country-Specific Patient Population of Choroidal Neovascularization 

9. Choroidal Neovascularization Current Treatment and Medical Practices

10. Choroidal Neovascularization Unmet Needs

11. Choroidal Neovascularization Emerging Therapies

12. Choroidal Neovascularization Market Outlook

13. Country-Wise Choroidal Neovascularization Market Analysis (2019–2032)

14. Choroidal Neovascularization Market Access and Reimbursement of Therapies

15. Choroidal Neovascularization Market Drivers

16. Choroidal Neovascularization Market Barriers

17.  Choroidal Neovascularization Appendix

18. Choroidal Neovascularization Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services